Patients’, physicians', nurses’ and pharmacists’ preferences toward the attributes of biological agents used in the treatment of rheumatic diseases in Italy (MK-0000-330) (CARA)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/47234
• EU PAS number:
  EUPAS6140
• Study ID:
  47234
• Official title and acronym:
  Patients’, physicians', nurses’ and pharmacists’ preferences toward the attributes of biological agents used in the treatment of rheumatic diseases in Italy (MK-0000-330) (CARA)
• DARWIN EU® study:
  No
• Study countries:
  Italy
• Study description:
  This study was conducted to determine patients’, physicians, nurses’ and pharmacists’ preferences toward the attributes of biological agents used in the treatment of three rheumatic conditions: rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, in Italy.
• Study status:
  Finalised

Research institutions and networks

Institutions

Merck & Co.

Multiple centres: 34 centres are involved in the study

Study timelines

Date when funding contract was signed

Actual: 18/09/2013

Study start date

Planned: 30/06/2014

Actual: 16/06/2014

Data analysis start date

Planned: 31/07/2015

Actual: 31/07/2015

Date of final study report

Planned: 30/06/2016

Actual: 30/06/2016

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Merck Sharp & Dohme LLC

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable